Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Richmond
Clinical trial register · Australia

Clinical Trials in Richmond, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Australia and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 3348 matching records held by the registry are in this view. Synced 18 Oct 2026, 03:18 UTC
3348
Studies in scope
all four open statuses
1802
Recruiting now
open to new participants
765
Lead sponsors
across recruiting studies
Top sites
Melbourne 1099 Adelaide 566 Sydney 511 Westmead 417 Clayton 408
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Sanofi6 Pfizer5 AbbVie5 DBV Technologies2 Amplia Therapeutics Limited2
Site location
Melbourne1099 Adelaide566 Sydney511 Westmead417 Clayton408
All 399 locations
Target enrolment
to

Trials with a site in Richmond

44 of 3348 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Australia
Start
Not yet open
AbbVie
Phase 3
520
Wollongong, Benowa, South Brisbane, Melbourne, Richmond, Murdoch, Nedlands
2026-11-30
Recruiting
AstraZeneca
Phase 3
950
Auchenflower, Benowa, Hobart, Kingswood, Nedlands, Port Macquarie, Randwick, Richmond
2026-09-16
Not yet open
Arovella Therapeutics Ltd
Phase 1
46
Sydney, Brisbane, Adelaide, Melbourne, Richmond
2026-08-20
Recruiting
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1
170
North Ryde, St Leonards, South Brisbane, Adelaide, Richmond
2026-08-13
Recruiting
Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma
NCT07249905Lymphoma, Waldenström Macroglobulinemia (WM), DLBCL - Diffuse Large B Cell Lymphoma, PMBCL
ModeX Therapeutics, An OPKO Health Company
Phase 1/2
180
Richmond, Nedlands
2026-04-13
Recruiting
Incyte Corporation
Phase 3
588
Macquarie Park, Chermside, Townsville, Woodville South, Melbourne, Richmond, Canberra, Perth
2026-04-09
Not yet open
Dilation Optimisation for Uniform Bioprosthetic Leaflet Expansion
NCT07430267Aortic Stenosis, TAVI(Transcatheter Aortic Valve Implantation)
The Alfred
Not applicable
250
Malvern, Melbourne, Richmond
2026-04-01
Recruiting
BioNTech SE
Phase 1/2
533
Clayton, Heidelberg Heights, Melbourne, Randwick, Richmond
2026-03-30
Active, closed
Amplia Therapeutics Limited
Phase 1/2
67
St Leonards, Richmond
2025-08-18
Recruiting
AbbVie
Phase 1/2
325
Liverpool, Waratah, Fitzroy, Richmond
2025-07-23
Recruiting
Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer
NCT06995677Low-grade NMIBC, FGFR Gene Amplification, FGFR Gene Alterations, FGFR3 Gene Alteration
DrugTYRA-300
Tyra Biosciences, Inc
Phase 2
90
Richmond
2025-06-27
Active, closed
DBV Technologies
Phase 3
480
Westmead, South Brisbane, Parkville, Richmond, Nedlands
2025-06-24
Active, closed
Sanofi
Phase 2
204
Kurralta Park, Richmond
2025-03-28
Recruiting
Cambridge University Hospitals NHS Foundation Trust
Phase 2
20
Melbourne, Richmond
2025-02-26
Active, closed
Kite, A Gilead Company
Phase 3
452
Camperdown, St Leonards, Adelaide, Richmond, Nedlands
2024-08-23
Recruiting
PulseSelect™ PFA Global Registry
NCT06393920Atrial Fibrillation
Medtronic Cardiac Ablation Solutions
Observational
1,950
Richmond
2024-07-23
Active, closed
Janssen Research & Development, LLC
Phase 1
108
Bedford Park, Box Hill, Camperdown, Richmond
2024-06-07
Active, closed
Pfizer
Phase 1
100
Liverpool, Waratah, Douglas, East Melbourne, Richmond
2024-02-20
By invitation
CRISPR Therapeutics AG
Observational
70
Camperdown, Melbourne, Nedlands, Richmond
2023-11-22
Recruiting
Hoffmann-La Roche
Phase 3
182
Waratah, Adelaide, Richmond
2023-10-22
Recruiting
Pfizer
Phase 4
80
Melbourne, Richmond
2023-10-03
Active, closed
Safety and Tolerability of a Novel Implantable Device for the Treatment of Erectile Dysfunction
NCT05650866Erectile Dysfunction Following Radical Prostatectomy
Comphya Australia
Not applicable
20
Fitzroy, Melbourne, North Melbourne, Richmond
2023-05-19
By invitation
Sanofi
Phase 2
70
Blacktown, Saint Leonards, Wollongong, Heidelberg, Melbourne, Richmond
2023-04-05
Active, closed
AbbVie
Phase 3
520
Westmead, Southport, Ballarat, Clayton, Malvern, Melbourne, Richmond, Subiaco
2023-03-15
Active, closed
DBV Technologies
Phase 3
600
Adelaide, Nedlands, Parkville, Richmond, South Brisbane, Westmead
2023-02-21
Recruiting
University of Sydney
Phase 4
280
Sydney, Annerley, Richmond
2023-02-16
Active, closed
Silence Therapeutics plc
Phase 1/2
69
Benowa, Hobart, Kurralta Park, Melbourne, Nedlands, Richmond
2023-01-26
Recruiting
Pfizer
Phase 3
1,060
Camperdown, Benowa, Fitzroy, Melbourne, Richmond
2022-11-10
Active, closed
AbbVie
Phase 1
283
Kogarah, Waratah, Clayton, Fitzroy Melbourne, Melbourne, Richmond, Murdoch
2022-10-20
Recruiting
Smith & Nephew, Inc.
Not applicable
234
Richmond
2022-08-30
Recruiting
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
NCT05475925LGLL - Large Granular Lymphocytic Leukemia, Primary Cutaneous Gamma-Delta T-Cell Lymphoma, Primary Cutaneous CD8+ Aggressive Epidermotropic T-Cell Lymphoma, Hepatosplenic T-cell Lymphoma
DrugDibotatug
Dren Bio
Phase 1/2
200
Clayton, Richmond, Nedlands
2022-07-13
Active, closed
Sanofi
Phase 3
531
Liverpool, Waratah, Wollongong, Adelaide, Melbourne, Richmond
2022-06-23
Active, closed
ACCENT: AMP945 in Combination With Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic Cancer
NCT05355298Pancreatic Cancer, PDAC, Pancreatic Ductal Adenocarcinoma
Amplia Therapeutics Limited
Phase 1/2
62
St Leonards, Waratah, Westmead, Greenslopes, Box Hill, Clayton, Richmond, St Albans
2022-05-31
Active, closed
AbbVie
Phase 1
34
Liverpool, Fitzroy, Fitzroy Melbourne, Heidelberg, Richmond
2022-05-17
Active, closed
Daiichi Sankyo
Phase 2
155
Richmond
2021-06-03
Active, closed
Pfizer
Phase 3
599
Camperdown, Wollongong, Brisbane, Southport, Woodville South, East Melbourne, Malvern, Richmond
2021-05-12
Active, closed
Geron Corporation
Phase 3
327
St Leonards, Herston, Hobart, Richmond
2021-04-12
Active, closed
Pfizer
Phase 2
187
Fitzroy, Melbourne, Richmond
2021-02-02
Recruiting
Sanofi
Phase 1/2
258
Wollongong, Melbourne, Richmond
2021-01-25
Recruiting
Pancreatic Cancer Early Detection Consortium
NCT04970056Pancreas Cancer, Pancreas Cyst, Pancreatic Ductal Adenocarcinoma, Genetic Predisposition
Arbor Research Collaborative for Health
Observational
20,000
Richmond
2020-09-18
Active, closed
Sanofi
Phase 3
337
Liverpool, Waratah, Wollongong, Fitzroy, Heidelberg West, Richmond, Nedlands
2020-06-16
Recruiting
Sumitomo Pharma America, Inc.
Phase 1/2
240
Adelaide, Box Hill, Clayton, Fitzroy, Melbourne, Richmond
2019-12-16
Active, closed
Sanofi
Observational
1,860
Kogarah, Sydney, Melbourne, Parkville, Richmond
2019-08-15
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,397
St Leonards, Wahroonga, Richmond
2018-12-24
Rows per page Showing 1–44 of 44
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Australian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 18 October 2026. https://priyalifescience.com/clinical-trials-australia/city/richmond

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Australia and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 3,348 studies in total at the last sync on 18 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 44 of those studies with a site in Richmond.

How many clinical trials are recruiting in Richmond?

18 of the 44 studies on this page are recruiting new participants as of the 18 Oct 2026, 03:18 UTC sync. A further 3 have not yet opened recruitment, 21 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Richmond), 44 studies
PhaseStudiesRecruitingShare
Phase 314431.8%
Phase 1/29620.5%
Phase 16113.6%
Phase 26213.6%
Observational429.1%
Not applicable316.8%
Phase 4224.5%

Most active sponsors

Lead sponsors with the most studies (Richmond)
Lead sponsorStudiesRecruiting
Sanofi61
AbbVie51
Pfizer52
Amplia Therapeutics Limited20
DBV Technologies20
Arbor Research Collaborative for Health11
Arovella Therapeutics Ltd10
AstraZeneca11
BioNTech SE11
Cambridge University Hospitals NHS Foundation Trust11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.